In a significant oncology breakthrough, BioNTech and its partner Duality Biologics demonstrated that their HER2-targeting antibody-drug conjugate (ADC), trastuzumab pamirtecan, surpassed Roche’s Kadcyla in a phase 3 clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and chemotherapy. The positive interim analysis met the primary endpoint of progression-free survival, marking BioNTech’s first phase 3 success in oncology and positioning Duality Biologics for potential regulatory filings in China. This advance offers hope for improved treatment options in a patient population with high unmet need.